| |
[摘要]：A positive-feedback mechanism between hypoxia-inducible factor 1 alpha (HIF-1 alpha) and metallothioneins (MTs) has been identified in different diseases. Both proteins have been independently proposed in the pathogenesis of inflammatory bowel disease (IBD); however, their relation has never been studied in the gut. In this study, we investigated the interaction between HIF-1 alpha and MTs in colonic epithelial cells and during experimental colitis. Dimethyloxalylglycine (DMOG) was used to subject colonocytes to hydroxylase inhibition and HIF-1 alpha stabilization in three experimental models (in vitro, in vivo and ex vivo). Small interfering RNA targeting HIF-1 alpha (siRNA-HIF) and MT (siRNA-MT) together with zinc-mediated MT induction were used to study the interaction between HIF-1 alpha and MT in HT29 cells. Acute colitis was induced in C57BL/6 mice using dextran sulphate sodium. MT expression and HIF-1 alpha protein levels were measured using quantitative real-time PCR and ELISA, respectively. Vascular endothelial growth factor (VEGF) expression was quantified as an indirect measure of HIF-1 transcriptional activity. DMOG down-regulated MT expression in HT29 cells, in freshly isolated human colonocytes and in colonocytes isolated from mice treated with DMOG (p < 0.05). SiRNA-HIF-treated cells displayed significant higher basal MT levels (p < 0.05) and an attenuated MT down-regulation after DMOG treatment. In turn, HIF-1 alpha stabilization was significantly lower in zinc-treated control cells, displaying high MT levels, compared to siRNA-MT cells treated with DMOG (p < 0.05). In the course of experimental colitis, MT and VEGF mRNA expression were inversely related. MTs were induced in the acute phase and down-regulated during recovery. Opposing results were observed for VEGF expression levels (p < 0.05). The present study underscores the inverse relation between HIF-1 alpha and MT expression in colonocytes and during experimental colitis. The manipulation of MTs may represent a novel therapeutic strategy for patients suffering from IBD. (C) 2011 Elsevier Inc. All rights reserved. |
|
